Immunoscore®, which evaluates the abundance of the CD3+ and CD8+ cells, was validated as an independent prognostic factor in colon cancer stage I–III6,7 and surpassed established clinical parameters such as T and N stage. This evidence concerns the gene CD8A and colonic neoplasm.